January 13, 2010 (Miami, Florida) — Aerosolized bronchodilators are independently associated with an increased risk for ventilator-associated pneumonia (VAP) in critically ill patients, according to ...

A retrospective cohort study of <29-week-gestation infants with evolving BPD defined at age 28 days within the Pediatric Health Information System database. Controlling for observed confounding with ...

Although there is significant improvement in managing asthma and chronic obstructive pulmonary disease (COPD) diseases, there is still a strong need in controlling symptoms to prevent hospitalizations ...

Individuals with pre-bronchodilator airflow obstruction appeared to be at significant risk for future COPD development, researchers reported in the American Journal of Respiratory and Critical Care ...

Researchers find a 28 percent greater risk of heart attack and stroke in older patients taking commonly prescribed drugs for chronic obstructive pulmonary disease (COPD). Canadian scientists are ...

Novartis' dual combination bronchodilator Utibron Neohaler inhalation powder for patients with chronic obstructive pulmonary disease (COPD) has received FDA approval. It is not indicated to treat ...

Please provide your email address to receive an email when new articles are posted on . Spirometry testing in the afternoon vs. morning was linked to a decreased likelihood for bronchodilator ...

Given the potential cardiovascular side effects associated with bronchodilators, clinicians may be hesitant to prescribe the therapy to COPD patients with CVD. Chronic obstructive pulmonary disease ...

And compared with the rest of the year, bronchodilator responsiveness was more common in winter months. HealthDay News — Patients are more likely to have positive bronchodilator responsiveness in the ...

Little evidence exists to support the widespread use of bronchodilators to treat children and adults with cystic fibrosis, according to a new systematic review of published research. Little evidence ...

July 1, 2011 (UPDATED July 21, 2011) — The US Food and Drug Administration (FDA) approved a once-daily bronchodilator — indacaterol maleate (Arcapta Neohaler, Novartis Pharmaceuticals) — for chronic ...